# Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

> **NCT07011810** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **BIOLOGICAL:** Axatilimab
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Skin Biopsy
- **PROCEDURE:** Skin Measurement

## Key facts

- **NCT ID:** NCT07011810
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2028-08-10
- **Final completion:** 2030-02-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011810, "Axatilimab for Sclerotic Chronic Graft-versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07011810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*